Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy

I. Pachón-Angona, B. Refouvelet, R. Andrýs, H. Martin, V. Luzet, I. Iriepa, I. Moraleda, D. Diez-Iriepa, MJ. Oset-Gasque, J. Marco-Contelles, K. Musilek, L. Ismaili,

. 2019 ; 34 (1) : 479-489.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19011935

We describe herein the design, multicomponent synthesis and biological studies of new donepezil + chromone + melatonin hybrids as potential agents for Alzheimer's disease (AD) therapy. We have identified compound 14n as promising multitarget small molecule showing strong BuChE inhibition (IC50 = 11.90 ± 0.05 nM), moderate hAChE (IC50 = 1.73 ± 0.34 μM), hMAO A (IC50 = 2.78 ± 0.12 μM), and MAO B (IC50 = 21.29 ± 3.85 μM) inhibition, while keeping a strong antioxidant power (3.04 TE, ORAC test). Consequently, the results reported here support the development of new multitarget Donepezil + Chromone + Melatonin hybrids, such as compound 14n, as a potential drug for AD patients cure.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19011935
003      
CZ-PrNML
005      
20251015111159.0
007      
ta
008      
190405s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/14756366.2018.1545766 $2 doi
035    __
$a (PubMed)30712420
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Pachón-Angona, Irene $u Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France.
245    10
$a Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy / $c I. Pachón-Angona, B. Refouvelet, R. Andrýs, H. Martin, V. Luzet, I. Iriepa, I. Moraleda, D. Diez-Iriepa, MJ. Oset-Gasque, J. Marco-Contelles, K. Musilek, L. Ismaili,
520    9_
$a We describe herein the design, multicomponent synthesis and biological studies of new donepezil + chromone + melatonin hybrids as potential agents for Alzheimer's disease (AD) therapy. We have identified compound 14n as promising multitarget small molecule showing strong BuChE inhibition (IC50 = 11.90 ± 0.05 nM), moderate hAChE (IC50 = 1.73 ± 0.34 μM), hMAO A (IC50 = 2.78 ± 0.12 μM), and MAO B (IC50 = 21.29 ± 3.85 μM) inhibition, while keeping a strong antioxidant power (3.04 TE, ORAC test). Consequently, the results reported here support the development of new multitarget Donepezil + Chromone + Melatonin hybrids, such as compound 14n, as a potential drug for AD patients cure.
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a Alzheimerova nemoc $x farmakoterapie $x metabolismus $7 D000544
650    _2
$a butyrylcholinesterasa $x metabolismus $7 D002091
650    _2
$a cholinesterasové inhibitory $x chemická syntéza $x chemie $x farmakologie $7 D002800
650    _2
$a chromony $x chemie $x farmakologie $7 D002867
650    _2
$a donepezil $x chemie $x farmakologie $7 D000077265
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a lidé $7 D006801
650    _2
$a melatonin $x chemie $x farmakologie $7 D008550
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a molekulární struktura $7 D015394
650    _2
$a monoaminoxidasa $x metabolismus $7 D008995
650    _2
$a inhibitory MAO $x chemická syntéza $x chemie $x farmakologie $7 D008996
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
700    1_
$a Refouvelet, Bernard $u Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France.
700    1_
$a Andrýs, Rudolf $u Faculty of Science, Department of Chemistry, University of Hradec Kralove, Hradec Kralove, Czech Republic. $7 xx0335645
700    1_
$a Martin, Helène $u PEPITE EA4267, Laboratoire de Toxicologie Cellulaire, University Bourgogne Franche-Comté, Besançon, France.
700    1_
$a Luzet, Vincent $u Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France.
700    1_
$a Iriepa, Isabel $u Department of Organic Chemistry and Inorganic Chemistry, Alcalà University, Madrid, Spain. $u Institute of Chemical Research Andrés M. del Río, Alcalà University, Madrid, Spain.
700    1_
$a Moraleda, Ignacio $u Department of Organic Chemistry and Inorganic Chemistry, Alcalà University, Madrid, Spain.
700    1_
$a Diez-Iriepa, Daniel $u Department of Organic Chemistry and Inorganic Chemistry, Alcalà University, Madrid, Spain. $u Institute of Chemical Research Andrés M. del Río, Alcalà University, Madrid, Spain.
700    1_
$a Oset-Gasque, María-Jesús $u Instituto de Investigación en Neuroquímica, Universidad Complutense de Madrid, Madrid, Spain. $u Department of Biochemistry and Molecular Biology, School of Pharmacy, Plaza de Ramòn y Cajal, Madrid, Spain.
700    1_
$a Marco-Contelles, José $u Laboratory of Medicinal Chemistry (IQOG, CSIC), Madrid, Spain.
700    1_
$a Musilek, Kamil $u Faculty of Science, Department of Chemistry, University of Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Ismaili, Lhassane $u Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France.
773    0_
$w MED00008009 $t Journal of enzyme inhibition and medicinal chemistry $x 1475-6374 $g Roč. 34, č. 1 (2019), s. 479-489
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30712420 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20251015111205 $b ABA008
999    __
$a ok $b bmc $g 1391245 $s 1050240
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 34 $c 1 $d 479-489 $i 1475-6374 $m Journal of enzyme inhibition and medicinal chemistry $n J Enzyme Inhib Med Chem $x MED00008009
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace